Abstract:

This article explores under-recognized applications of amlexanox, a compound showing promise for patients with chronic inflammatory conditions, including mast cell activation syndrome (MCAS), asthma, and autoimmune diseases such as lupus. Increasing numbers of patients present with symptoms of mast cell overactivity, chronic inflammatory conditions, and dependence on anti-inflammatory medications and steroids to control their pain and inflammation. To address these challenges and reduce polypharmacy, we present 3 case studies exploring the integration of amlexanox in patient treatment regimens. Patient data were obtained from medical records of prescribing physicians and dispensing pharmacies. We discuss amlexanox’s pharmacology, availability, dosing, and self-reported patient outcomes, including enhanced symptom management and reduced corticosteroid reliance. Amlexanox is a compound deserving of greater attention and formal research for its potential applications in patients diagnosed with conditions such as MCAS, cancer, erectile dysfunction, nonalcoholic fatty liver disease (NAFLD), diabetes, asthma, atopic dermatitis, lupus, long COVID and more.